CA2657634A1 - Compositions and methods for the treatment of mucormycosis and other fungal diseases - Google Patents
Compositions and methods for the treatment of mucormycosis and other fungal diseases Download PDFInfo
- Publication number
- CA2657634A1 CA2657634A1 CA002657634A CA2657634A CA2657634A1 CA 2657634 A1 CA2657634 A1 CA 2657634A1 CA 002657634 A CA002657634 A CA 002657634A CA 2657634 A CA2657634 A CA 2657634A CA 2657634 A1 CA2657634 A1 CA 2657634A1
- Authority
- CA
- Canada
- Prior art keywords
- mucormycosis
- antifungal agent
- iron chelating
- composition
- fungal condition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract 17
- 206010061418 Zygomycosis Diseases 0.000 title claims 33
- 201000007524 mucormycosis Diseases 0.000 title claims 33
- 208000031888 Mycoses Diseases 0.000 title 1
- 229940121375 antifungal agent Drugs 0.000 claims abstract 37
- 239000003429 antifungal agent Substances 0.000 claims abstract 37
- 230000002538 fungal effect Effects 0.000 claims abstract 21
- 239000000797 iron chelating agent Substances 0.000 claims abstract 19
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract 14
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims abstract 14
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 claims abstract 10
- 108010049047 Echinocandins Proteins 0.000 claims abstract 7
- TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 claims abstract 7
- 150000001875 compounds Chemical class 0.000 claims abstract 7
- 229960001489 deferasirox Drugs 0.000 claims abstract 7
- FMSOAWSKCWYLBB-VBGLAJCLSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N(N\C(N\1)=C\2C(C=CC=C/2)=O)C/1=C\1C(=O)C=CC=C/1 FMSOAWSKCWYLBB-VBGLAJCLSA-N 0.000 claims abstract 7
- 229960003266 deferiprone Drugs 0.000 claims abstract 7
- 229910052742 iron Inorganic materials 0.000 claims abstract 7
- 150000004291 polyenes Chemical class 0.000 claims abstract 7
- 239000000589 Siderophore Substances 0.000 claims abstract 5
- 230000000069 prophylactic effect Effects 0.000 claims abstract 3
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical group O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims 16
- 241000222122 Candida albicans Species 0.000 claims 6
- 239000012678 infectious agent Substances 0.000 claims 6
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims 4
- 201000002909 Aspergillosis Diseases 0.000 claims 4
- 208000036641 Aspergillus infections Diseases 0.000 claims 4
- 206010007134 Candida infections Diseases 0.000 claims 4
- 108010020326 Caspofungin Proteins 0.000 claims 4
- 108010021062 Micafungin Proteins 0.000 claims 4
- 241000235388 Mucorales Species 0.000 claims 4
- 240000005384 Rhizopus oryzae Species 0.000 claims 4
- 235000013752 Rhizopus oryzae Nutrition 0.000 claims 4
- 201000003984 candidiasis Diseases 0.000 claims 4
- 229960000730 caspofungin acetate Drugs 0.000 claims 4
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims 4
- 229960004884 fluconazole Drugs 0.000 claims 4
- 229960004130 itraconazole Drugs 0.000 claims 4
- 229960002159 micafungin Drugs 0.000 claims 4
- PIEUQSKUWLMALL-YABMTYFHSA-N micafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@H](O)CC(N)=O)[C@H](O)[C@@H](O)C=2C=C(OS(O)(=O)=O)C(O)=CC=2)[C@@H](C)O)=O)=NO1 PIEUQSKUWLMALL-YABMTYFHSA-N 0.000 claims 4
- 229960001589 posaconazole Drugs 0.000 claims 4
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical group O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims 4
- OGUJBRYAAJYXQP-IJFZAWIJSA-N vuw370o5qe Chemical group CC(O)=O.CC(O)=O.C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 OGUJBRYAAJYXQP-IJFZAWIJSA-N 0.000 claims 4
- 241000293034 Apophysomyces elegans Species 0.000 claims 2
- 241000228212 Aspergillus Species 0.000 claims 2
- 241000228193 Aspergillus clavatus Species 0.000 claims 2
- 241000228197 Aspergillus flavus Species 0.000 claims 2
- 241001225321 Aspergillus fumigatus Species 0.000 claims 2
- 241000351920 Aspergillus nidulans Species 0.000 claims 2
- 241001465318 Aspergillus terreus Species 0.000 claims 2
- 206010005098 Blastomycosis Diseases 0.000 claims 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 2
- 241000222173 Candida parapsilosis Species 0.000 claims 2
- 241000222178 Candida tropicalis Species 0.000 claims 2
- 201000007336 Cryptococcosis Diseases 0.000 claims 2
- 241000221204 Cryptococcus neoformans Species 0.000 claims 2
- 241000235555 Cunninghamella Species 0.000 claims 2
- 241000235554 Cunninghamellaceae Species 0.000 claims 2
- 208000004770 Fusariosis Diseases 0.000 claims 2
- 201000002563 Histoplasmosis Diseases 0.000 claims 2
- 208000003539 Hyalohyphomycosis Diseases 0.000 claims 2
- 241000144128 Lichtheimia corymbifera Species 0.000 claims 2
- 241000235395 Mucor Species 0.000 claims 2
- 206010064458 Penicilliosis Diseases 0.000 claims 2
- 241000235645 Pichia kudriavzevii Species 0.000 claims 2
- 241000235525 Rhizomucor pusillus Species 0.000 claims 2
- 241000235527 Rhizopus Species 0.000 claims 2
- 241000293024 Rhizopus microsporus var. rhizopodiformis Species 0.000 claims 2
- 206010041736 Sporotrichosis Diseases 0.000 claims 2
- 241000222126 [Candida] glabrata Species 0.000 claims 2
- 229940091771 aspergillus fumigatus Drugs 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 229940095731 candida albicans Drugs 0.000 claims 2
- 208000032343 candida glabrata infection Diseases 0.000 claims 2
- 229940055022 candida parapsilosis Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000001370 mediastinum Anatomy 0.000 claims 2
- 206010033072 otitis externa Diseases 0.000 claims 2
- 210000004303 peritoneum Anatomy 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 210000003437 trachea Anatomy 0.000 claims 2
- 210000002620 vena cava superior Anatomy 0.000 claims 2
- -1 voricoazole Chemical compound 0.000 claims 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83109906P | 2006-07-13 | 2006-07-13 | |
| US60/831,099 | 2006-07-13 | ||
| US89762007P | 2007-01-26 | 2007-01-26 | |
| US60/897,620 | 2007-01-26 | ||
| US90407507P | 2007-02-27 | 2007-02-27 | |
| US60/904,075 | 2007-02-27 | ||
| PCT/US2007/016065 WO2008008537A2 (en) | 2006-07-13 | 2007-07-13 | Combi) compositions for the treatment of mucormycosis. comprising iron chelator and antifungal agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2657634A1 true CA2657634A1 (en) | 2008-01-17 |
Family
ID=38610625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002657634A Abandoned CA2657634A1 (en) | 2006-07-13 | 2007-07-13 | Compositions and methods for the treatment of mucormycosis and other fungal diseases |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100129434A1 (enExample) |
| EP (2) | EP2043636A2 (enExample) |
| JP (2) | JP2009543788A (enExample) |
| KR (1) | KR20090036587A (enExample) |
| AU (1) | AU2007272781B2 (enExample) |
| BR (1) | BRPI0714221A2 (enExample) |
| CA (1) | CA2657634A1 (enExample) |
| CL (1) | CL2007002026A1 (enExample) |
| IL (1) | IL196389A0 (enExample) |
| MA (1) | MA30625B1 (enExample) |
| MX (1) | MX2009000506A (enExample) |
| NO (1) | NO20090565L (enExample) |
| NZ (1) | NZ574862A (enExample) |
| RU (1) | RU2464024C2 (enExample) |
| SG (1) | SG177122A1 (enExample) |
| TN (1) | TN2009000004A1 (enExample) |
| TW (1) | TWI448285B (enExample) |
| WO (1) | WO2008008537A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ614255A (en) * | 2009-03-19 | 2015-03-27 | Los Angeles Biomed Res Inst | Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases |
| US8980876B2 (en) | 2010-10-28 | 2015-03-17 | The Procter & Gamble Company | Inhibition of microbial growth by aconitase inhibition |
| MX2015003729A (es) * | 2012-11-12 | 2015-06-15 | Cipla Ltd | Composiciones farmaceuticas de dosis fija que comprende deferasirox y deferiprona. |
| US11229685B2 (en) | 2013-01-29 | 2022-01-25 | Case Western Reserve University | Fungal iron acquisition inhibitors and uses thereof |
| US20160199361A1 (en) * | 2013-08-19 | 2016-07-14 | Rutgers, The State University Of New Jersey | Method of Inducing An Anti-Retroviral Immune Response By Counter-Acting Retro-Virus Induced Anti-Apoptosis |
| US20170239182A1 (en) * | 2014-08-13 | 2017-08-24 | Mark E. Hayes | Pharmaceutical formulations of and methods to prepare chelating agents for efficient metal removal treatment systems |
| WO2016025611A2 (en) * | 2014-08-13 | 2016-02-18 | Zoneone Pharma, Inc. | Pharmaceutical formulations of chelating agents as a metal removal treatment system |
| WO2017035582A1 (en) * | 2015-08-31 | 2017-03-09 | The University Of Adelaide | Methods and products for preventing and/or treating microorganism infections comprising iron chelators and non-iron porphyrins |
| EP3454944B1 (en) * | 2016-05-13 | 2022-07-13 | The Brigham and Women's Hospital, Inc. | Volatile metabolite profiles for the diagnosis and treatment of mucorales fungi |
| FR3095755A1 (fr) * | 2019-05-10 | 2020-11-13 | Balmes Transplantation | Nouveaux médicaments cytoprotecteurs |
| CN113905715B (zh) | 2019-06-28 | 2025-04-15 | 宝洁公司 | 光增强处理方法 |
| JP2023057423A (ja) * | 2021-10-11 | 2023-04-21 | 国立大学法人 熊本大学 | ムコール症治療薬 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8329043D0 (en) * | 1983-10-31 | 1983-11-30 | Hider R C | Pharmaceutical compositions |
| US4698431A (en) * | 1985-11-12 | 1987-10-06 | The United States Of America As Represented By The United States Department Of Energy | Hydroxypyridonate chelating agents |
| PH31594A (en) * | 1993-09-30 | 1998-11-03 | Janssen Pharmaceutica Nv | Oral formulations on an antifungal. |
| TW533205B (en) * | 1996-06-25 | 2003-05-21 | Novartis Ag | Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition |
| WO1999009997A1 (en) * | 1997-08-26 | 1999-03-04 | Board Of Regents, The University Of Texas System | Edta and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections |
| EP1223308B1 (de) * | 2000-12-16 | 2007-01-24 | ALSTOM Technology Ltd | Komponente einer Strömungsmaschine |
| GB0223978D0 (en) | 2002-10-15 | 2002-11-20 | Novartis Ag | Organic compound |
| ITMI20022447A1 (it) * | 2002-11-19 | 2004-05-20 | Carlo Ghisalberti | Uso di piridinoni nel trattamento della purpura capillare ed affezioni cutanee correlate. |
| AU2003302274A1 (en) * | 2002-12-31 | 2004-07-29 | Novartis Ag | Aerosolizable pharmaceutical formulation for fungal infection therapy |
| WO2004108114A2 (en) * | 2003-03-31 | 2004-12-16 | Dinesh Shantilal Patel | Anti-fungal composition and a process for its manufacture |
| DE10356409B4 (de) * | 2003-11-28 | 2006-12-28 | Biofrontera Discovery Gmbh | Neues Arzneimittel Oxachelin und Derivate |
-
2007
- 2007-07-12 TW TW096125466A patent/TWI448285B/zh not_active IP Right Cessation
- 2007-07-12 CL CL200702026A patent/CL2007002026A1/es unknown
- 2007-07-13 WO PCT/US2007/016065 patent/WO2008008537A2/en not_active Ceased
- 2007-07-13 US US12/373,511 patent/US20100129434A1/en not_active Abandoned
- 2007-07-13 RU RU2009104961/15A patent/RU2464024C2/ru not_active IP Right Cessation
- 2007-07-13 AU AU2007272781A patent/AU2007272781B2/en not_active Ceased
- 2007-07-13 JP JP2009519562A patent/JP2009543788A/ja active Pending
- 2007-07-13 MX MX2009000506A patent/MX2009000506A/es not_active Application Discontinuation
- 2007-07-13 EP EP07796874A patent/EP2043636A2/en not_active Withdrawn
- 2007-07-13 NZ NZ574862A patent/NZ574862A/en not_active IP Right Cessation
- 2007-07-13 CA CA002657634A patent/CA2657634A1/en not_active Abandoned
- 2007-07-13 BR BRPI0714221-8A patent/BRPI0714221A2/pt not_active IP Right Cessation
- 2007-07-13 KR KR1020097002793A patent/KR20090036587A/ko not_active Ceased
- 2007-07-13 EP EP11003922A patent/EP2412371A1/en not_active Withdrawn
- 2007-07-13 SG SG2011075421A patent/SG177122A1/en unknown
-
2009
- 2009-01-08 IL IL196389A patent/IL196389A0/en unknown
- 2009-01-12 TN TN2009000004A patent/TN2009000004A1/fr unknown
- 2009-02-04 MA MA31613A patent/MA30625B1/fr unknown
- 2009-02-05 NO NO20090565A patent/NO20090565L/no not_active Application Discontinuation
-
2012
- 2012-11-27 JP JP2012258262A patent/JP2013040212A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008008537A2 (en) | 2008-01-17 |
| SG177122A1 (en) | 2012-01-30 |
| AU2007272781B2 (en) | 2012-10-18 |
| MA30625B1 (fr) | 2009-08-03 |
| EP2043636A2 (en) | 2009-04-08 |
| RU2009104961A (ru) | 2010-08-20 |
| NO20090565L (no) | 2009-03-30 |
| MX2009000506A (es) | 2009-05-20 |
| IL196389A0 (en) | 2009-09-22 |
| KR20090036587A (ko) | 2009-04-14 |
| WO2008008537A3 (en) | 2008-04-24 |
| EP2412371A1 (en) | 2012-02-01 |
| BRPI0714221A2 (pt) | 2013-01-01 |
| TW200816994A (en) | 2008-04-16 |
| US20100129434A1 (en) | 2010-05-27 |
| RU2464024C2 (ru) | 2012-10-20 |
| NZ574862A (en) | 2012-02-24 |
| TWI448285B (zh) | 2014-08-11 |
| JP2009543788A (ja) | 2009-12-10 |
| TN2009000004A1 (en) | 2010-08-19 |
| JP2013040212A (ja) | 2013-02-28 |
| CL2007002026A1 (es) | 2008-06-06 |
| AU2007272781A1 (en) | 2008-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2657634A1 (en) | Compositions and methods for the treatment of mucormycosis and other fungal diseases | |
| JP2009543788A5 (enExample) | ||
| Rauseo et al. | Hope on the horizon: novel fungal treatments in development | |
| Hoenigl et al. | The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin | |
| Calvo et al. | Antifungal prophylaxis during the early postoperative period of lung transplantation | |
| Stewart et al. | How urgent is the need for new antifungals? | |
| Fortún et al. | Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high‐risk liver transplantation recipients: a propensity score analysis | |
| RU2009137946A (ru) | Производные пиридазинона для применения в качестве ингибиторов глюкансинтазы | |
| IL275121B1 (en) | Antifungal agents History of pyridine derivatives transformed into heterocycles | |
| JP2017517498A5 (enExample) | ||
| Bormann et al. | Review of the pharmacology and clinical studies of micafungin | |
| NO20074945L (no) | Antifungal sammensetning omfattende sertaconalzol og hydrokortison og/eller en antibakteriell kinolinforbindelse | |
| Martinez | An update on the use of antifungal agents | |
| Chen et al. | Total saponins of Panax notoginseng protected rabbit iliac artery against balloon endothelial denudation injury | |
| Fortún et al. | Fungal infection in solid organ recipients | |
| Joseph et al. | Antifungal therapy in eye infections: new drugs, new trends | |
| Phoompoung et al. | Treatment of non-aspergillus mold infections: a focus on mucormycosis and fusariosis | |
| Valgus | What’s new in antifungals? | |
| Kauffman | New antifungal agents | |
| Ghannoum et al. | Anidulafungin: a potent antifungal that targets Candida and Aspergillus | |
| Pappas | The role of azoles in the treatment of invasive mycoses: review of the Infectious Diseases Society of America guidelines | |
| Lockhart et al. | Antifungal agents | |
| Henig et al. | Antifungal Agents and Their Role in the Management of Pulmonary Aspergillosis | |
| Cheung | Invasive fungal infections-What are the options? | |
| McCreary et al. | Isavuconazole: Has it saved us? A pharmacotherapy review and update on clinical experience |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20150714 |